Weekly Rundown: Small-Cap Stocks with Upcoming Catalysts (June 23–27)

We’re tracking the latest updates from small-cap companies—covering recent filings, fresh announcements, and noteworthy investor events. This roundup is designed to keep you informed and ahead of the curve. Take a look at the key highlights we’re watching for the week of June 23–27.

Companies Participating at the iAccess Alpha Virtual Best Ideas Summer Investment Conference (June 24–25, 2025):

MOB INUV DCGO BEAT DAIO SURG GAIA

Companies Participating at the J.P. Morgan Energy, Power, Renewables & Mining Conference (June 24–25, 2025, New York):

TTI SHLS

Companies Participating at the Northland Capital Virtual Growth Conference (June 25, 2025):

TTI TALK AIOT MCHX RZLV RBBN NOTE

Companies Participating at the Oppenheimer Innovators in Immunology & Inflammation (I&I) Summit (June 25, 2025):

ALLO IFRX AVTX ATXS

Companies Participating at the 15th Annual ROTH London Conference (June 24–26, 2025, Four Seasons Hotel London at Park Lane, London, UK):

CRNT WULF ARBE MX ODYS RCT RMNI FTCI SHLS RZLV

Other Companies with Key Catalysts This Week:

INVE > The company will showcase its NFC- and BLE-enabled smart packaging for Digital Product Passports and supply chain intelligence at the AIPIA & AWA Smart Packaging World Congress 2025 (June 23–24, Amsterdam), enabling traceability, compliance, sustainability, and consumer engagement.

AMPX > Amprius CTO Dr. Ionel Stefan will present "Breakthrough Silicon Anode Technology: Ready for Market, Built for Scale" at the Advanced Automotive Battery Conference (AABC) Europe on Thursday, June 26 at 8:35 a.m. CET / Wednesday, June 25 at 11:35 p.m. PT.

QSI > At the upcoming Festival of Genomics & Biodata Boston, Melissa Deck, Director of Platform at Liberate Bio, will deliver a featured talk on June 24, 2025: "Precision Proteomics: Advancing Drug Development with Next-Gen Protein Sequencing™ (NGPS™)," highlighting how Quantum-Si's Platinum® Pro is revolutionizing protein research.

IPHA > Members of the company’s executive team will participate in two upcoming virtual investor conferences: the H.C. Wainwright 3rd Annual Immune Cell Engager Conference on June 24, 2025, and Wolfe Research Virtual Biotech Day on June 26, 2025.

CALC > Upcoming symposium entitled "Auxora for the Treatment of AKI" at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology meeting being held June 24-26 in Vicenza, Italy.

TALK > The company will participate in the Truist Healthcare Disruptors & Digital Health Conference in New York, featuring 1x1 investor meetings on Tuesday, June 24, 2025, and a panel discussion titled "Addressing the Mental Health Crisis" with CEO Dr. Jon Cohen on Wednesday, June 25, 2025, at 2:40 p.m. ET.

SDA > WeBull EV Stock Webinar Tuesday, June 24th.

HOTH > Will host a KOL event on June 24, 2025, at 3:30 p.m. EST to highlight progress on HT-001, a promising treatment for EGFR-inhibitor-induced toxicities. The event will cover HT-001’s compelling mechanism of action, an evolving IP strategy, and key clinical milestones, including updates on the ongoing Phase 2 trial. Attendees will also receive a broader pipeline and IP update. Investors, media, partners, and healthcare professionals are invited to attend, with access details to be shared closer to the event date.

ANVS > Will host a live webcast where Maria Maccecchini, Ph.D., President and CEO, will provide updates and answer questions from the audience on June 24, 2025 4:30 PM EDT.

ABSI > TD Cowen 4th Annual Tools/Dx Revolution (Dana Point, CA) on June 22-25. Morgan Stanley 4th Annual Life Sciences Data and AI Conference (New York, NY) on June 24.

OTLK > Will participate in a Virtual Investor Lunch Break Event on Wednesday, June 25, 2025 at 12:00 PM ET.

SVCO > Will host a tech talk exploring "The Diffusion of Innovation: Investing in the Ecosystem Expansion" on Wednesday, June 25, 2025 at 10:00 AM Eastern Time.

IMUX > Dr. Vitt and Mr. Tardio will attend the Accelerating Bio-Innovation (ABI) Conference 2025, taking place June 23–25 in Cambridge, MA. The event is organized in partnership with Royalty Pharma and focuses on advancing innovation across the biopharma ecosystem.

CMMB > At BSG Live'25, taking place June 23–26, 2025, in Glasgow, UK, Dr. Douglas Thorburn will deliver an oral presentation on CM-101, a novel monoclonal antibody targeting CCL24, in patients with primary sclerosing cholangitis. The talk will highlight results from the SPRING Study. Dr. Thorburn serves as Divisional Clinical Director for Liver and Digestive Health at the Royal Free London NHS Trust and Professor of Hepatology at UCL.

ANIX > Will host an investor webcast presentation on June 26, 2025 at 2:00 PM EDT.

WHWK > Dave Lennon, PhD, President and CEO, and David Dornan, PhD, Chief Scientific Officer, will participate in the virtual H.C. Wainwright "HCW@Home" series on Thursday, June 26, 2025.

SKYQ > Will host a live investor webinar on Thursday, June 26 at 11:00 a.m. PDT / 2:00 p.m. EDT to present a strategic overview of the company’s recent milestones and explain how these achievements align with and support its broader growth plan.

BCTX > Will be conducting a virtual investor presentation on Thursday, June 26, at 12:00 PM EDT, arranged by Renmark Financial Communications Inc. The company welcomes stakeholders, investors, and individual followers to register and attend this live event.

XHLD > On June 26, 2025, at 12:00 PM ET, TEN Holdings will participate in the Skyline Signature Series Webinar, hosted by Skyline Corporate Communications Group LLC. This live virtual event offers public companies a platform to present their story directly to financial professionals through a CEO presentation. After TEN Holdings' presentation, there will be a live Q&A session where the audience can submit questions to be answered in real time by the company’s management.

JAGX > Family company Napo Pharmaceuticals announced that a late-breaker abstract submitted by Napo, highlighting significant new results in adult breast cancer patients from the OnTarget study, has been accepted for oral rapid e-poster presentation at the MASCC Annual Meeting, taking place June 26-28, 2025, in Seattle. The presentation’s authors include Jaguar’s Chief Scientific Officer, Dr. Pravin Chaturvedi, who also chairs Napo’s Scientific Advisory Board, alongside leading oncologists and cancer patient advocates.

OSTX > The Company is awaiting feedback by mid-June 2025 from a Type D meeting with FDA regarding the statistical analysis plan to be used in an End of Phase 2 meeting for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma.

LCTX > Additional presenters for the upcoming 3rd Annual Spinal Cord Injury Investor Symposium (3rd SCIIS), which will be held virtually with interactive and on-demand sessions starting June 27, 2025. CEO Brian M. Culley expressed enthusiasm about the strong lineup of confirmed presenters, noting that this year’s event is expected to provide the most comprehensive and relevant discussions on spinal cord injury to date.

MYND > Announced the expansion of its award-winning ActivPanel display portfolio with the global launch of two additional displays, complementing the existing ActivPanel 10 and ActivPanel 10 Premium. These new offerings will be introduced with phased availability. The company plans to showcase its complete lineup of ActivPanel displays at ISTELive 2025, taking place in San Antonio, TX, from June 29 to July 2.

AREC > The Critical Minerals Forum will take place on June 26, 2025, in New York City, bringing together stakeholders from across the critical minerals sector to promote supply chain transparency and resilience. Mark Jensen, Chief Executive Officer of American Resources Corp, will be attending and participating in panel discussions; to schedule a meeting.

IBIO > Mouse study shows IBIO-610 alone drives an overall body weight loss of 8.9%*, and prevents weight regain following GLP-1 treatment in obese mice, results of which will be presented at ADA on Monday June 23rd from 12:30 p.m. to 1:30 p.m. CST.

LTRY > announced the signing of an amended Stock Purchase Agreement to acquire Nook Holdings Limited, a sports, health, and wellness incubator based in Dubai, for approximately $2.5 million in an all-cash deal. The acquisition will give Lottery.com a 90% ownership stake in Nook and is expected to close by June 30, 2025, supporting the company’s global expansion strategy.

ASBP > Phase 1 trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation scheduled for completion mid-June 2025.

AKAN > On March 5, 2025, the Company entered into a Share Exchange Agreement with First Towers & Fibers Corp. (FTFC) and its shareholders to complete a business combination, whereby FTFC will become a wholly owned subsidiary. Under the agreement, shareholders will exchange their FTFC shares for approximately 15.3 million Company shares or receive $14.1 million in cash payable 18 months after closing. The Company also agreed to assume FTFC’s outstanding options and debt. Additionally, the Company has provided FTFC unsecured loans totaling $400,000 with 20% interest and plans to raise between $4 million and $10 million in further financing within seven months post-closing. The agreement’s closing deadline was extended to June 30, 2025.

NRXP > Its drug candidates target the NMDA receptor pathway. The company plans to submit two lead drugs—NRX-101 (a combination of D-cycloserine and lurasidone) and NRX-100 (a ketamine formulation)—for FDA approval in Q2 2025, with decisions expected by year-end under the PDUFA timeline.

ZVSA > The first patient is expected to begin therapy by the end of Q2 2025 in a Phase 2a proof-of-concept trial for the Cholesterol Efflux Mediator™ VAR 200 targeting diabetic kidney disease (DKD). Additionally, a preclinical proof-of-concept study for obesity-related cardiometabolic disease using the Inflammasome ASC Inhibitor IC 100 is planned to start by the same timeframe. The company has also submitted a grant request to the Michael J. Fox Foundation (MJFF) for funding Parkinson’s disease animal model studies, with a funding decision expected in June 2025.

KAPA > The company is conducting two ongoing clinical trials for its lead drug, ENV105: a Phase 2 trial in prostate cancer and a Phase 1 trial in EGFR-dependent non-small cell lung cancer. Safety and interim efficacy results are expected to be available by the end of the second quarter of 2025.

ARTL > Artelo's lead FABP5 inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. Data from the first Phase 1 trial with ART26.12 is anticipated in Q2 2025.

HOWL > Company announces development of its proprietary INDUCER™ T cell engager molecules; development candidate targeted by the end of the second quarter of 2025.

SGMO > Fabry Disease: The product candidate continues to be well tolerated, and a pivotal data readout is expected by the end of the second quarter of 2025.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.